FEB 1 4 2002 TO THE PRADEWARK OF THE PRA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent

Attorney Docket: 258/193

MAULE	
In re the Application of:	Group Art Unit: 1632
WANG, Kangsheng	Examiner: To be assigned
Serial No.: 09/781,046	
Filed: 02/08/2001	RECEIVED
For: A METHOD AND SYSTEM FOR	
INTRODUCING A GENE INTO A HUMAN	FEB 2 0 7002
STEM CELL	TECH CENTER 1600/2900
TRANSM	

Commissioner for Patents Washington, D.C. 20231

Sir:

Applicant submits the following documents with this Transmittal Letter.

- (1) Information Disclosure Statement;
- (2) Form PTO-1449; and
- (3) References EE; BJ through DA; DG through DJ.

Respectfully submitted,

LYON & LYON LLP

Reg. No. 47,997

Dated: February 4, 2002

By: Annul Constant Samuel N. Tiu

633 West Fifth Street, Suite 4700 Los Angeles, California 90071-2066 (213) 489-1600

LA-225904.1

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Rowena R. Estrada

Name of Person Mailing Paper

Pebruary 04, 2002

Date of Deposit

Signature of Person Mailing Paper



TECH CENTER 1600/2900

Patent 258/193



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:	Group Art Unit: 163 ECEIVED
WANG, Kangsheng	Examiner: to be assigned B 2 0 2002
Serial No.: 09/781,046	TEU = JEN 1600/2900
Filed: 02/08/2001)
For: A METHOD AND SYSTEM FOR INTRODUCING A GENE INTO A HUMAN STEM CELL))

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner. Copies of documents AA, AB-BI are not submitted since they have already been provided to the Examiner in the parent application, U.S. Patent Application Serial No. 09/537,861. Copies of documents DB through DF are also not provided since they were cited by the Examiner in the same parent application.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

Information Disclosure Statement Filing Provision:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.
on the § 1.311	merits, b	OS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action out before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR
S		The fee due under 37 CFR § 1.17(p) is submitted herewith.
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
· ·	3 or a No ent unde	OS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR otice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A r 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted
STATEMENT UNDER 37 CFR § 1.97(e):		
	Each it	em contained in this IDS was first cited in any communication from a foreign patent office
in a co	unterpar	t foreign application not more than three months prior to the filing of this IDS.
	No iten	n contained in this IDS was cited in a communication from a foreign patent office in a
counter	rpart for	eign application, and, to the knowledge of the person signing this statement after making
reasona	able inqu	airy, no item of information contained in this IDS was known to any individual designated
in 37 C	EFR § 1.:	56(c) more than three months prior to the filing of this IDS.

	PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:
	A check in the amount of is enclosed for the above fee(s).
	Please charge to Deposit Account No. 12-2475 for the above fee(s).
The Co	ommissioner is authorized to charge any fees required by the filing of these papers, and to credit
any ov	erpayment to Lyon & Lyon's Deposit Account No. 12-2475.
	Respectfully submitted,
	LYON & LYON LLP
Dated:	2/4/02 By:
	Samuel N. Tiu

Reg. No. 47,997

22249

LYON & LYON LLP 633 W. Fifth Street, Suite 4700 Los Angeles, CA 90071